The present invention is directed to a compound having the general structure of formula (1):
useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
The present invention is directed to a compound having the general structure of formula (1):
useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
[EN] CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS<br/>[FR] ANTAGONISTES DE CHIMIOKINES CXCR1 ET CXCR2
申请人:SCHERING CORP
公开号:WO2005113534A2
公开(公告)日:2005-12-01
The present invention is directed to a compound having the general structure of formula (1) useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.